In settlement, Myland doesn’t admit guilt for misclassifying life-saving device.
EpiPen maker Mylan agreed to pay $465 million in a settlement with federal regulators over its pricing practices
Mylan, the marker of the EpiPen, has agreed to pay the federal government a $465 million settlement after it allegedly overcharged government healthcare agencies for the medicine, according to a release from the firm. Mylan had unde...
(Reuters) - Mylan NV on Friday said it will pay $465 million to settle the question of whether it underpaid U.S. government healthcare programs by misclassifying its EpiPen emergency allergy treatment.
Mylan said the settlement, after the government had said it improperly classified EpiPen as a generic drug, did not imply any admission of wrongdoing.